Somscan Aps

Rigshospitalet

Curasight A/s

Trt Innovations Aps

Curasight Aps

Fluoguide A/s

Andreas Kjaer

Morten Persson

Jacob Madsen

Liselotte Højgaard

Palle Rasmussen

Ulrich Knigge

Michael Ploug

Malene Brandt-larsen

Jytte Oxboel

Liselotte HØJGAARD

Carsten Haagen Nielsen

There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

Ga- andCu-NODAGA-E[c(RGDyK)]for use as PET tracers in the imaging of angiogenesis in humans

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.

PET tracer for imaging of neuroendocrine tumors

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

177-Lu labeled peptide for site-specific uPAR-targeting

Pet tracer for imaging of neuroendocrine tumors

There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.

uPAR targeting peptide for use in peroperative optical imaging of invasive cancer

Growing community of inventors

Frederiksberg, Denmark

Andreas Kjaer